Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer

This study has been withdrawn prior to enrollment.
(Lack of accrual (no subjects enrolled) and funding expires in June, 2014.)
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
University of Michigan Cancer Center
ClinicalTrials.gov Identifier:
NCT01642732
First received: March 24, 2012
Last updated: April 30, 2014
Last verified: April 2014
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: April 2023
  Estimated Primary Completion Date: April 2023 (Final data collection date for primary outcome measure)